Lessons from a Case of Oromandibular Mucormycosis Treated with Surgery and a Combination of Amphotericin B Lipid Formulation plus Caspofungin

A rare case of oromandibular Rhizopus oryzae infection is described in a 55-year-old woman with acute myeloid leukaemia and decompensated diabetes mellitus. The infection developed during induction chemotherapy when the patient was neutropenic. She was treated with a combination of amphotericin B lipid formulation and caspofungin plus surgery. Debridement surgery included excision of the lower lip, chin, floor of the mouth, a portion of the tongue, as well as mandibular resection at the level of the horizontal branches. Eight weeks of combined antifungal therapy were followed by secondary prophylaxis with amphotericin B lipid formulation during consolidation chemotherapy after achieving complete response of both leukaemia and mucormycosis. Reconstructive surgery was carried out including insertion of a new biomaterial porous mandibular prosthesis, which showed excellent functionality after long-term follow-up, followed by several plastic surgery procedures once good tolerability and no adverse effects of the prosthesis were observed. This case shows that a well-coordinated multidisciplinary approach is critical to increase the chances of clinical success in this life-threatening infection.

[1]  B. Spellberg,et al.  Recent advances in the management of mucormycosis: from bench to bedside. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  R. Goldberg,et al.  Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  T. Peláez,et al.  Synergistic Effect of Posaconazole and Caspofungin against Clinical Zygomycetes , 2007, Antimicrobial Agents and Chemotherapy.

[4]  M. Rinaldi,et al.  In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents , 2007, Antimicrobial Agents and Chemotherapy.

[5]  D. Kontoyiannis,et al.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  N. Madinger,et al.  Surgery and Treatment with High-Dose Liposomal Amphotericin B for Eradication of Craniofacial Zygomycosis in a Patient with Hodgkin's Disease Who Had Undergone Allogeneic Hematopoietic Stem Cell Transplantation , 2005, Journal of Clinical Microbiology.

[7]  B. Spellberg,et al.  Caspofungin Inhibits Rhizopus oryzae 1,3-β-d-Glucan Synthase, Lowers Burden in Brain Measured by Quantitative PCR, and Improves Survival at a Low but Not a High Dose during Murine Disseminated Zygomycosis , 2005, Antimicrobial Agents and Chemotherapy.

[8]  B. Spellberg,et al.  Combination Therapy with Amphotericin B Lipid Complex and Caspofungin Acetate of Disseminated Zygomycosis in Diabetic Ketoacidotic Mice , 2005, Antimicrobial Agents and Chemotherapy.

[9]  L. Pagano,et al.  Mucormycosis in hematologic patients. , 2004, Haematologica.

[10]  S. Paydaş,et al.  Mucormycosis of the tongue in a patient with acute lymphoblastic leukemia: a possible relation with use of a tongue depressor. , 2003, The American journal of medicine.

[11]  C. Buchwald,et al.  Unexpected Expansive Paranasal Sinus Mucormycosis , 2003, ORL.

[12]  J. Chluba,et al.  Survival analysis of rats implanted with porous titanium tracheal prosthesis. , 2002, The Annals of thoracic surgery.

[13]  E. Anaissie,et al.  Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected withAspergillus Species and Other Filamentous Fungi: Maximum Tolerated Dose Study , 2001, Antimicrobial Agents and Chemotherapy.

[14]  J. Rachel,et al.  Volume-length impact of lateral jaw resections on complication rates. , 1999, Archives of otolaryngology--head & neck surgery.

[15]  E. Anaissie,et al.  Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  D. Schuller,et al.  Factors involved in long- and short-term mandibular plate exposure. , 1997, Archives of otolaryngology--head & neck surgery.

[17]  P. Gullane,et al.  The Free Flap and Plate in Oromandibular Reconstruction: Long‐Term Review and Indications , 1995, Plastic and reconstructive surgery.

[18]  J. Lowe,et al.  Pulmonary mucormycosis: results of medical and surgical therapy. , 1994, The Annals of thoracic surgery.

[19]  P. Freedman,et al.  Mucormycosis of the oral cavity. , 1993, Oral surgery, oral medicine, and oral pathology.